Popularity #2,725Earnings in 3d
Inventiva (ADR) (IVA)
Developing lanifibranor, an oral MASH candidate, through a pivotal global trial.
$3.56
vs last close−0.09 (−2.60%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 162.83% | 84.64M ADS | |
|---|---|---|---|
| 88 holders · as of Jun 30, 2026 | |||
| Insiders | 20.72% | 10.77M ADS | |
| 2 holders · as of Sep 5, 2023 | |||
| Adds to | 183.55% | ||
51.98M ADS as of Sep 7, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2022 annual report; nothing newer is on file here.
These groups come from separate filings that can overlap, so they add to 183.55%; nothing is left for Other.
13F, as of Jun 30, 2026
88 holders · 84.64M shares · 31 new positions · 67 increased · 7 reduced · 9 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Caligan Partners LP | 8.16M | 15.70% | +3.19M | Aug 14, 2026 |
| Samsara Biocapital, LLC | 6.31M | 12.15% | +1.12M | Aug 14, 2026 |
| Paradigm Biocapital Advisors LP | 4.00M | 7.69% | 0 | Aug 14, 2026 |
| Andera Partners | 3.63M | 6.99% | +1.82M | Jul 22, 2026 |
| Adar1 Capital Management, LLC | 3.61M | 6.94% | +1.43M | Aug 14, 2026 |
| Millennium Management LLC | 3.51M | 6.76% | +524.6K | Aug 14, 2026 |
| Nantahala Capital Management, LLC | 2.69M | 5.17% | +2.69Mnew | Aug 19, 2026 |
| Trails Edge Capital Partners, LP | 2.66M | 5.11% | 0 | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Invus Public Equities, L.P. | 10.60% | 14.81M | 13G | Jul 31, 2025 |
| Andera Partners | 7.70% | 14.11M | 13G | Feb 17, 2026 |
| Sofinnova Crossover I SLP | 5.60% | 12.33M | 13G | Feb 17, 2026 |
| Yiheng Capital Partners, L.P. | 5.46% | 7.60M | 13G | Nov 13, 2025 |
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
Not reported.